lornoxicam and Back-Pain

Efficacy of different nonsteroid anti-inflammatory drugs (voltaren (diclofenac), movalis (meloxicam), nimesil (nimesulide) and xefocam (lornoxicam) in stopping the pain syndrome and normalization of motor activity was assessed in 140 patients with dorsalgia using the Visual Analogous Scale and the modified Waddel scale. Moreover, we suggest a method for calculating a treatment efficacy coefficient. The most effective drug in the treatment of back pain was xefocam (lornoxicam). Nimesil (nimesulide) was somewhat less effective. Other drugs did not reveal any significant effect. Xefocam was well-tolerated: adverse effects were rare compared to other drugs used in the study.

Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Outpatients; Pain Measurement; Piroxicam; Sulfonamides; Treatment Outcome

Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Humans; Male; Piroxicam; Pseudolymphoma; Skin Diseases

Serum pepsinogen I was determined radioimmunologically in 18 patients suffering from lumbar backache syndromes. These patients were then treated with lornoxicam 4 mg twice daily over a period of 2 weeks. No significant increase in the serum pepsinogen I level was found in 17 (94.4%) of cases. Using the serum pepsinogen I as a parameter for the integrity of the gastric mucosa, this suggests good gastric tolerance of lornoxicam.

Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Female; Gastric Mucosa; Humans; Male; Middle Aged; Pepsinogens; Piroxicam